Crystal structure of a natural light-gated anion channelrhodopsin
- University of Texas Health Science Center at Houston, McGovern Medical School, United States
- Swiss Light Source, Paul Scherrer Institute, Switzerland
Abstract
The anion channelrhodopsin GtACR1 from the alga Guillardia theta is a potent neuron-inhibiting optogenetics tool. Presented here, its X-ray structure at 2.9 Å reveals a tunnel traversing the protein from its extracellular surface to a large cytoplasmic cavity. The tunnel is lined primarily by small polar and aliphatic residues essential for anion conductance. A disulfide-immobilized extracellular cap facilitates channel closing and the ion path is blocked mid-membrane by its photoactive retinylidene chromophore and further by a cytoplasmic side constriction. The structure also reveals a novel photoactive site configuration that maintains the retinylidene Schiff base protonated when the channel is open. These findings suggest a new channelrhodopsin mechanism, in which the Schiff base not only controls gating, but also serves as a direct mediator for anion flux.
Data availability
Diffraction data have been deposited in PDB under the accession code 6EDQ.
-
Crystal Structure of the Light-Gated Anion Channelrhodopsin GtACR1Protein Data Bank, 6EDQ.
Article and author information
Author details
Funding
National Institutes of Health (R01GM027750)
- John L Spudich
National Institutes of Health (U01MH109146)
- John L Spudich
Welch Foundation (AU-0009)
- John L Spudich
American Heart Association (18TPA34230046)
- Lei Zheng
Hermann Eye Fund
- John L Spudich
Marie-Skłodowska-Curie (701647)
- Chia-Ying Huang
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2019, Li et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,741
- views
-
- 491
- downloads
-
- 37
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Crystal structure of a natural light-gated anion channelrhodopsin
eLife 8:e41741.
https://doi.org/10.7554/eLife.41741
Further reading
-
eLife has published papers on topics related to the molecular structure and functional mechanisms of a diverse array of ion channel proteins.
-
- Biochemistry and Chemical Biology
- Cancer Biology
Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. This feature is exploited by cancer therapies to either increase RS to unbearable levels or inhibit checkpoint kinases involved in the DNA damage response. Thus far, treatments that combine these two strategies have shown promise but also have severe adverse effects. To identify novel, better-tolerated anticancer combinations, we screened a collection of plant extracts and found two natural compounds from the plant, Psoralea corylifolia, that synergistically inhibit cancer cell proliferation. Bakuchiol inhibited DNA replication and activated the checkpoint kinase CHK1 by targeting DNA polymerases. Isobavachalcone interfered with DNA double-strand break repair by inhibiting the checkpoint kinase CHK2 and DNA end resection. The combination of bakuchiol and isobavachalcone synergistically inhibited cancer cell proliferation in vitro. Importantly, it also prevented tumor development in xenografted NOD/SCID mice. The synergistic effect of inhibiting DNA replication and CHK2 signaling identifies a vulnerability of cancer cells that might be exploited by using clinically approved inhibitors in novel combination therapies.
